Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

43.57 +0.03 (+0.07%)

Delayed Quote Updated: 2:11 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Bear Market Bets In Biotech ↗

February 07, 2022

Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.

Via Talk Markets

What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗

February 01, 2022

Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:

Via Benzinga

BofA Downgrades Ionis After Vupanorsen Setback: Are There Upcoming Catalysts That Can Help The Stock? ↗

February 01, 2022

Ionis Pharmaceuticals Inc (NASDAQ: IONS) announced on Monday the discontinuation of the Vupanorsen clinical development program. Following this, there are no high-impact catalysts for the next 12...

Via Benzinga

Will Moderna Sidestep The Looming Sales Cliff After FDA Approves Covid Shot? ↗

January 31, 2022

Currently, analysts expect Moderna sales to drop off after 2022.

Via Investor's Business Daily

Pfizer Backs Out Of Heart-Disease Deal, Leaving Ionis Stock To Crumble ↗

January 31, 2022

Pfizer signed on to develop a high triglycerides treatment in November 2019.

Via Investor's Business Daily

Why Are Ionis Pharmaceuticals Shares Tanking Today? ↗

January 31, 2022

Pfizer Inc (NYSE: PFE) and Ionis Pharmaceuticals Inc (NASDAQ: IONS)

Via Benzinga

Where Ionis Pharmaceuticals Stands With Analysts ↗

December 14, 2021

Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed ...

Via Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Monday, Jan. 31, 2022: NFLX, BB, IONS, NXPI, EA ↗

January 31, 2022

Today's 5 Stock Ideas: Netflix (NFLX) - Shares up premarket. Citigroup upgraded the stock from Neutral to Buy and announced a $450 price target. Also, Co-CEO Reed Hastings...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 31, 2022

Gainers Madrigal Pharmaceuticals (NASDAQ:MDGL) shares rose 14.9% to $64.8 during Monday's pre-market session. The market value of their outstanding shares is at $1.1...

Via Benzinga

Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder ↗

January 24, 2022

The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

January 20, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗

January 14, 2022

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...

Via Benzinga

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...

Via Benzinga

Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More ↗

December 10, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021 ↗

December 14, 2021

Upgrades According to Wells Fargo, the prior rating for Douglas Emmett Inc (NYSE:

Via Benzinga

The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré ↗

December 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 07, 2021

Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 18.35% to $22.96 during Tuesday's pre-market session. The company's market cap stands at $3.6 billion....

Via Benzinga

Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder ↗

December 07, 2021

Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and...

Via Benzinga

Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial ↗

November 24, 2021

Pfizer Inc (NYSE: PFE) has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe...

Via Benzinga

How Alnylam Pharmaceuticals Could Take On Pfizer With A 'Catalyst-Rich' 2022 ↗

November 22, 2021

Alnylam is working on a drug that could tackle transthyretin cardiomyopathy.

Via Investor's Business Daily

Barron's Most Recent Picks And Pans: General Electric, Pfizer, Walt Disney And More ↗

November 13, 2021

This weekend's Barron's cover story examines the revival of mall stocks. Other featured articles discuss why small-cap stocks are the next big thing and some energy...

Via Benzinga

Ionis Pharmaceuticals, inc (IONS) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

IONS earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗

November 03, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...

Via Benzinga

Topics Retirement

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Why Ionis Pharmaceuticals Stock Is Down 13% This Week ↗

October 22, 2021

An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial.

Via The Motley Fool

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops ↗

October 18, 2021

Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal.

Via Investor's Business Daily

Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial ↗

October 18, 2021

Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.